Literature DB >> 32947486

A Systematic Review of the Hematopoietic Acute Radiation Syndrome (H-ARS) in Canines and Non-human Primates: Acute Mixed Neutron/Gamma vs. Reference Quality Radiations.

Thomas J MacVittie1, Ann M Farese1, William E Jackson2.   

Abstract

A systematic review of relevant studies that determined the dose response relationship (DRR) for the hematopoietic (H) acute radiation syndrome (ARS) in the canine relative to radiation quality of mixed neutron:gamma radiations, dose rate, and exposure uniformity relative to selected reference radiation exposure has not been performed. The datasets for rhesus macaques exposure to mixed neutron:gamma radiation are used herein as a species comparative reference to the canine database. The selection of data cohorts was made from the following sources: Ovid Medline (1957-present), PubMed (1954-present), AGRICOLA (1976-present), Web of Science (1954-present), and US HHS RePORT (2002-present). The total number of hits across all search sites was 3,077. Several referenced, unpublished, non-peer reviewed government reports were unavailable for review. Primary published studies using canines, beagles, and mongrels were evaluated to provide an informative and consistent review of mixed neutron:gamma radiation effects to establish the DRRs for the H-ARS. Secondary and tertiary studies provided additional information on the hematologic response or the effects on hematopoietic progenitor cells, radiation dosimetry, absorbed dose, and organ dose. The LD50/30 values varied with neutron quality, exposure aspect, and mixed neutron:gamma ratio. The reference radiation quality varied from 250 kVp or 1-2 MeV x radiation and Co gamma radiation. A summary of a published review of a data set describing the DRR in rhesus macaques for mixed neutron:gamma radiation exposure in the H-ARS is included for a comparative reference to the canine dataset. The available evidence provided a reliable and extensive database that characterized the DRR for the H-ARS in canines and young rhesus macaques exposed to mixed neutron:gamma radiations of variable energy relative to 250 kVp, 1-2 MeV x radiation and Co gamma, and uniform and non-uniform total-body irradiation without the benefit of medical management. The mixed neutron:gamma radiation showed an energy-dependent RBE of ~ 1.0 to 2.0 relative to reference radiation exposure within both species. A marginal database described the DRR for the gastrointestinal (GI)-ARS. Medical management showed benefit in both species relative to the mixed neutron:gamma as well as exposure to reference radiation. The DRR for the H-ARS was characterized by steep slopes and relative LD50/30 values that reflected the radiation quality, exposure aspect, and dose rate over a range in time from 1956-2012.

Entities:  

Mesh:

Year:  2020        PMID: 32947486      PMCID: PMC9438931          DOI: 10.1097/HP.0000000000001319

Source DB:  PubMed          Journal:  Health Phys        ISSN: 0017-9078            Impact factor:   2.922


  95 in total

1.  Neutron beam characteristics from the University of California 60 in. Cyclotron.

Authors:  E TOCHILIN; G D KOHLER
Journal:  Health Phys       Date:  1958-12       Impact factor: 1.316

2.  Acute effects of gamma radiation in primates.

Authors:  R G ALLEN; F A BROWN; L C LOGIE; D R ROVNER; S G WILSON; R W ZELLMER
Journal:  Radiat Res       Date:  1960-05       Impact factor: 2.841

3.  The effects of total-body irradiation of dogs with simulated fission neutrons.

Authors:  E L ALPEN; O S SHILL; E TOCHILIN
Journal:  Radiat Res       Date:  1960-03       Impact factor: 2.841

4.  Radiation sickness in the monkey.

Authors:  E ELDRED; W V TROWBRIDGE
Journal:  Radiology       Date:  1954-01       Impact factor: 11.105

5.  Citrulline as a Biomarker in the Murine Total-Body Irradiation Model: Correlation of Circulating and Tissue Citrulline to Small Intestine Epithelial Histopathology.

Authors:  Jace W Jones; Gregory Tudor; Fei Li; Yan Tong; Barry Katz; Ann M Farese; Thomas J MacVittie; Catherine Booth; Maureen A Kane
Journal:  Health Phys       Date:  2015-11       Impact factor: 1.316

6.  The acute mortality response of the miniature pig to pulsed mixed gamma-neutron radiations.

Authors:  D Wise; C L Turbyfill
Journal:  Radiat Res       Date:  1970-03       Impact factor: 2.841

7.  A mortality determinant in nonuniform exposures of the mammal.

Authors:  V P Bond; C V Robinson
Journal:  Radiat Res Suppl       Date:  1967

8.  The relative biological effectiveness of mixed fission-neutron-gamma radiation on the hematopoietic syndrome in the canine: effect of therapy on survival.

Authors:  T J MacVittie; R Monroy; R M Vigneulle; G H Zeman; W E Jackson
Journal:  Radiat Res       Date:  1991-10       Impact factor: 2.841

9.  Filgrastim improves survival in lethally irradiated nonhuman primates.

Authors:  Ann M Farese; Melanie V Cohen; Barry P Katz; Cassandra P Smith; Allison Gibbs; Daniel M Cohen; Thomas J MacVittie
Journal:  Radiat Res       Date:  2012-12-04       Impact factor: 2.841

10.  The Effect of Radiation Dose and Variation in Neupogen® Initiation Schedule on the Mitigation of Myelosuppression during the Concomitant GI-ARS and H-ARS in a Nonhuman Primate Model of High-dose Exposure with Marrow Sparing.

Authors:  Thomas J MacVittie; Alexander W Bennett; Ann M Farese; Cheryl Taylor-Howell; Cassandra P Smith; Allison M Gibbs; Karl Prado; William Jackson
Journal:  Health Phys       Date:  2015-11       Impact factor: 2.922

View more
  2 in total

1.  Pharmacokinetic and metabolomic studies with a BIO 300 Oral Powder formulation in nonhuman primates.

Authors:  Yaoxiang Li; Michael Girgis; Meth Jayatilake; Artur A Serebrenik; Amrita K Cheema; Michael D Kaytor; Vijay K Singh
Journal:  Sci Rep       Date:  2022-08-05       Impact factor: 4.996

2.  Radioprotection of deinococcal exopolysaccharide BRD125 by regenerating hematopoietic stem cells.

Authors:  Hae Ran Park; Ji Hee Lee; Hyun Jung Ji; Sangyong Lim; Ki Bum Ahn; Ho Seong Seo
Journal:  Front Oncol       Date:  2022-09-26       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.